SARS-CoV-2 BioBlock nasal and throat spray product is launching. Cuesta Law Office’s partners and sworn attorneys Britta Oltjer and Gretta Oltjer-Timberg have advised Chemi-Pharm on the preparation and conclusion of the consortium contract. Cuesta’s lawyers will also soon assist the company in developing and concluding a contract for the construction of the production building. Britta Oltjer also assisted the company in concluding a consortium agreement. At the end of 2020, Chemi-Pharm entered into a cooperation agreement with the University of Tartu, Estonian University of Life Sciences, Teadus ja Tegu OÜ and Icosagen Cell Factory OÜ for the development of the antibody-based SARS-CoV-2 BioBlock nasal and throat spray. SARS-CoV-2 BioBlock is a nasal and throat spray that can be sprayed into the nose and mouth and which neutralizes COVID-19 virus particles and thus protects people from COVID-19 virus. This collaborative project has a broader objective in the fight against the COVID-19 virus. It is by its nature a very interesting, detailed, and challenging project involving researchers, partners, officials and potential resellers, as well as export markets. Kristo Timberg, the company’s CEO, has introduced the company’s future plans as follows: “In collaboration with Icosagen Cell Factoryga, a new concept is in development that would involve the fight against other viruses as well.”
